 |
|
Oral Antiplatelet Therapy
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We are concerned about some of the recommendations in the Clinical Review of oral antiplatelet agents by Drs Tran and Anand1 that we believe are inconsistent with clinical trial data and current clinical practice guidelines. First, the use of combined aspirin and extended-release dipyridamole (ASA-ERDP) in patients with concomitant symptomatic CAD is described as questionable, due to a theoretical risk of coronary steal. The European Stroke Prevention Study 2 trial of ASA-ERDP2 included more than 2000 patients with TIA or stroke and with coexisting CAD. No safety problems with ERDP were noted in this population, and the 18% relative benefit of ASA-ERDP over aspirin alone for prevention of stroke in this subgroup was consistent with that observed in the overall trial3 ; patients with cerebrovascular disease and a history of CAD who were treated with ASA-ERDP had no increase in the risk of cardiac events compared with . . . [Full Text of this Article]
Richard A. Bernstein, MD, PhD
r-bernstein@northwestern.edu
Davee Department of Neurology
Feinberg School of Medicine of Northwestern University
Chicago, Ill
Gregory W. Albers, MD
Department of Neurology
Stanford University
Palo Alto, Calif
RELATED ARTICLES
Oral Antiplatelet Therapy
Javier Borja
JAMA. 2005;293(7):793.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy—Reply
Huyen Tran and Sonia S. Anand
JAMA. 2005;293(7):794-795.
EXTRACT
| FULL TEXT
Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease
Huyen Tran and Sonia S. Anand
JAMA. 2004;292(15):1867-1874.
ABSTRACT
| FULL TEXT
|
